AU2011256444B2 - Spiro isoxazoline compounds as SSTR5 antagonists - Google Patents

Spiro isoxazoline compounds as SSTR5 antagonists Download PDF

Info

Publication number
AU2011256444B2
AU2011256444B2 AU2011256444A AU2011256444A AU2011256444B2 AU 2011256444 B2 AU2011256444 B2 AU 2011256444B2 AU 2011256444 A AU2011256444 A AU 2011256444A AU 2011256444 A AU2011256444 A AU 2011256444A AU 2011256444 B2 AU2011256444 B2 AU 2011256444B2
Authority
AU
Australia
Prior art keywords
halogen
mmol
heterocycle
pct
cioalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2011256444A
Other languages
English (en)
Other versions
AU2011256444A1 (en
Inventor
Jianming Bao
Joseph L. Duffy
Paul E. Finke
Zahid Hussain
Revathi Katipally
Remond Moningka
Debra L. Ondeyka
Michael A. Plotkin
F. Anthony Romero
Patrick Shao
Sriram Tyagarajan
Feng Ye
Yi Zang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2011256444A1 publication Critical patent/AU2011256444A1/en
Application granted granted Critical
Publication of AU2011256444B2 publication Critical patent/AU2011256444B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2011256444A 2010-05-18 2011-05-13 Spiro isoxazoline compounds as SSTR5 antagonists Expired - Fee Related AU2011256444B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34568310P 2010-05-18 2010-05-18
US61/345,683 2010-05-18
PCT/US2011/036367 WO2011146324A1 (en) 2010-05-18 2011-05-13 Spiro isoxazoline compounds as sstr5 antagonists

Publications (2)

Publication Number Publication Date
AU2011256444A1 AU2011256444A1 (en) 2012-10-18
AU2011256444B2 true AU2011256444B2 (en) 2014-07-10

Family

ID=44991994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011256444A Expired - Fee Related AU2011256444B2 (en) 2010-05-18 2011-05-13 Spiro isoxazoline compounds as SSTR5 antagonists

Country Status (8)

Country Link
US (1) US20130040978A1 (enExample)
EP (1) EP2571356A4 (enExample)
JP (1) JP2013529210A (enExample)
AR (1) AR081401A1 (enExample)
AU (1) AU2011256444B2 (enExample)
CA (1) CA2799414A1 (enExample)
TW (1) TW201200524A (enExample)
WO (1) WO2011146324A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
MX2014015265A (es) 2012-06-14 2015-08-12 Basf Se Metodos plaguicidas que utilizan compuestos de 3-piridiltiazol sustituido y derivados para combatir plagas de animales.
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
US9663534B2 (en) 2013-12-17 2017-05-30 Merck Sharp & Dohme Corp. Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
CN104945416B (zh) * 2014-03-24 2017-11-17 中国科学院上海药物研究所 一类螺异噁唑啉衍生物、其制备方法及医药用途
JPWO2015146561A1 (ja) * 2014-03-26 2017-04-13 住友精化株式会社 臭化芳香族エステル化合物の製造方法
EP3174537B1 (en) * 2014-07-29 2021-06-23 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
WO2018077699A1 (en) 2016-10-25 2018-05-03 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138028A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3573952B1 (en) 2017-01-26 2021-07-14 Boehringer Ingelheim International GmbH Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
JP7106564B2 (ja) 2017-03-16 2022-07-26 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレータとその使用
JP7365347B2 (ja) 2018-02-12 2023-10-19 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターおよびその使用
JP7431813B2 (ja) * 2018-09-18 2024-02-15 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
US20230050965A1 (en) * 2019-12-03 2023-02-16 Kallyope, Inc. Sstr5 antagonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
JP2024506715A (ja) 2021-02-17 2024-02-14 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターの結晶形態
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
CN114230552B (zh) * 2021-12-29 2023-11-03 江苏广域化学有限公司 三氟甲氧基二苯并噻吩、其制备方法及相关中间体的制备方法
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
CN120752056A (zh) 2023-03-27 2025-10-03 思可海雅药品株式会社 生长激素分泌促进剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070179167A1 (en) * 2005-08-26 2007-08-02 Cottrell Kevin M Inhibitors of serine proteases
US20080269271A1 (en) * 2005-05-19 2008-10-30 Gruenenthal Gmbh Substituted Spiro Compounds and Their Use for Producing Pain-Relief Medicaments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
CN101253171B (zh) * 2005-09-02 2011-06-15 霍夫曼-拉罗奇有限公司 苯并噁唑、噁唑并吡啶、苯并噻唑和噻唑并吡啶衍生物
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269271A1 (en) * 2005-05-19 2008-10-30 Gruenenthal Gmbh Substituted Spiro Compounds and Their Use for Producing Pain-Relief Medicaments
US20070179167A1 (en) * 2005-08-26 2007-08-02 Cottrell Kevin M Inhibitors of serine proteases

Also Published As

Publication number Publication date
WO2011146324A1 (en) 2011-11-24
TW201200524A (en) 2012-01-01
CA2799414A1 (en) 2011-11-24
EP2571356A4 (en) 2013-11-20
EP2571356A1 (en) 2013-03-27
AR081401A1 (es) 2012-08-29
US20130040978A1 (en) 2013-02-14
AU2011256444A1 (en) 2012-10-18
JP2013529210A (ja) 2013-07-18

Similar Documents

Publication Publication Date Title
AU2011256444B2 (en) Spiro isoxazoline compounds as SSTR5 antagonists
US8742110B2 (en) Spiroxazolidinone compounds
US9834563B2 (en) Antidiabetic substituted heteroaryl compounds
JP2013531037A (ja) スピロ環式化合物
AU2012240122B2 (en) Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
AU2008276568A1 (en) Beta carboline derivatives as antidiabetic compounds
AU2012339870A1 (en) Substituted cyclopropyl compounds useful as GPR119 agonists
WO2013096093A1 (en) Compounds as dgat-1 inhibitors
WO2011159657A1 (en) Bicyclic heterocycle derivatives and methods of use thereof
EP3097101A1 (en) Isoquinoline derivatives as mgat2 inhibitors
EP2760855B1 (en) Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
WO2012024179A1 (en) Substituted amide derivatives as dgat-1 inhibitors
AU2011282989A1 (en) Imidazole derivatives
WO2012064569A1 (en) Imidazole derivatives
AU2012264651A1 (en) Imidazole derivatives
EP2931718A1 (en) Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
WO2012047772A2 (en) Imidazole derivatives
WO2013068328A1 (en) Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
TW202430517A (zh) 含有3-氟-4-羥基苯甲醯胺之抑制劑及/或降解劑與其用途

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee